Impact de la réponse histologique complète à la chimiothérapie néo-adjuvante pour cancer du sein selon le sous-type moléculaire

Cirier, Julien; Body, G.; Jourdan, Michel; Bedouet, L.; Fleurier, C.; Pilloy, Joseph; Arbion, Flavie; Ouldamer, Lobna

doi:10.1016/j.gofs.2017.08.002

Cited by 5 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Achievement of pCR led to significantly better overall survival in women with HER2positive tumors and also to significantly better locoregional survival in women treated for TNBC. Predictive factors of pCR were a high pathologic grade, the HER2 molecular subtype, positive estrogenic hormonal receptors, and a positive HER2 receptor (10). Assessing nearly 14,000 women from a contemporary United States database, Haque et al (11) examined the relationship between response to NACT and molecular subtype.…”

Section: Subtypes Tumor Size and Gradementioning

confidence: 99%

Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review

Alamoodi

2024

EJBH

View full text Add to dashboard Cite

Achieving pathological complete response (pCR) is the desired end result of using neoadjuvant therapy in responders.• Identifying factors that determine pCR in breast cancer patients can help guide treatment, hence individualizing it.• Achieving pCR in the breast correlates well with pCR in the axilla; this can result in the de-escalation of axillary surgery.• pCR determinants should be used in combination to achieve optimal results. Therefore, standardization of these factors is essential.

show abstract

Section: Subtypes Tumor Size and Gradementioning

confidence: 99%

Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review

Alamoodi

2024

EJBH

View full text Add to dashboard Cite

show abstract

Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients

Turiján-Espinoza

Ruiz-Rodríguez

Uresti-Rivera

et al. 2021

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort

et al. 2019

View full text Add to dashboard Cite

Background. The majority of patients with breast cancer in Colombia are admitted into oncological centers at locally advanced stages of the disease (53.9%). The aim of this study was to describe the pathological response obtained with neoadjuvant chemotherapy (NACT) according to the molecular classification of breast cancer in patients with locally advanced tumors treated within the National Cancer Institute (NCI) Functional Breast Cancer Unit (FBCU) in Bogotá, Colombia. Materials and Methods. This was an observational, descriptive, historical cohort study of patients with locally advanced breast cancer treated within the NCI FBCU. Results. We included 414 patients who received NACT and surgical management. Most patients had luminal B HER2negative tumors (n = 134, 32.4%). The overall rate of pathological complete response (pCR) ypT0/ypN0 was 15.2% (n = 63). Tumors that presented the highest rate of pCR were pure HER2, at 40.5% (n = 15; odds ratio [OR], 6.7); however, with a follow-up of 60 months, only the triple negative tumors presented a statistically significant difference for event-free survival (EFS; median recurrence time, 18 months; range, 1-46) and overall survival (OS; median follow-up, 31 months; range 10-57). The molecular subtype that most recurrences presented was luminal B HER2 negative, at 38.3% (n = 28). The majority of recurrences (93.2 %; n = 68; OR, 5.9) occurred in patients in whom no pathological response was obtained (Chevallier 3 and 4). Conclusion. Pathological response in locally advanced tumors is related to the molecular subtype of breast cancer, finding higher pCR rates in pure HER2 and triple-negative tumors. A direct relationship was found between disease recurrences and the pathological response, evidencing greater tumor recurrence in patients who did not respond to NACT (Chevallier 3 and 4). EFS and OS were greater in patients with pCR, with statistical significance only in triplenegative tumors. The Oncologist 2019;24:e1360-e1370 Implications for Practice: This research article is of scientific interest, because it describes the clinical and pathological features and analyzes the correlation between pathological response to neoadjuvant chemotherapy and the molecular classification of locally advanced breast cancer in patients treated in the National Cancer Institute in Bogotá, Colombia. It was found that pathological response is related to the molecular subtype of breast cancer. In addition, there is a direct relationship between disease recurrences and pathological response. The survival results were greater in patients with pathological complete response. Global Health and CancerAccording to data from GLOBOCAN 2018, 13,380 new cases of breast cancer were diagnosed in Colombia within that year (an incidence of 44.1 per 100,000 people), being 13.1% of the total of patients diagnosed with cancer in the country. Among the female population, cases of breast cancer rank first in incidence, at 24.8%. Mortality in both sexes has a rate of 11.9 per 100,000 people, representing 3,702 dea...

show abstract

Impact de la réponse histologique complète à la chimiothérapie néo-adjuvante pour cancer du sein selon le sous-type moléculaire

Cited by 5 publications

References 41 publications

Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review

Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review

Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients

Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort

Contact Info

Product

Resources

About